X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
male (24) 24
female (23) 23
index medicus (23) 23
middle aged (21) 21
aged (19) 19
adult (16) 16
chemotherapy (13) 13
cancer (12) 12
oncology (12) 12
gastroenterology & hepatology (11) 11
aged, 80 and over (10) 10
treatment outcome (10) 10
gemcitabine (9) 9
medicine & public health (9) 9
retrospective studies (9) 9
carcinoma (8) 8
embroidering (7) 7
paper (7) 7
sewing (7) 7
survival (7) 7
textiles (7) 7
tufting (7) 7
cisplatin (6) 6
deoxycytidine - analogs & derivatives (6) 6
patients (6) 6
trial (6) 6
abdominal surgery (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
biliary tract cancer (5) 5
biliary tract neoplasms - drug therapy (5) 5
clinical trials (5) 5
combination (5) 5
disease-free survival (5) 5
gastroenterology (5) 5
human necessities (5) 5
pancreatic cancer (5) 5
prognosis (5) 5
research (5) 5
stomach neoplasms - pathology (5) 5
stomach neoplasms - surgery (5) 5
surgery (5) 5
analysis (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - therapeutic use (4) 4
deoxycytidine - administration & dosage (4) 4
diagnosis (4) 4
follow-up studies (4) 4
hygiene (4) 4
japan (4) 4
medical or veterinary science (4) 4
patient outcomes (4) 4
pharmacology & pharmacy (4) 4
pharmacology/toxicology (4) 4
preparations for medical, dental, or toilet purposes (4) 4
resection (4) 4
s-1 (4) 4
tumors (4) 4
adenocarcinoma - surgery (3) 3
animals (3) 3
antineoplastic agents - adverse effects (3) 3
articles (3) 3
biliary tract neoplasms - pathology (3) 3
biopsy (3) 3
cancer research (3) 3
cancer therapies (3) 3
care and treatment (3) 3
chemistry (3) 3
deoxycytidine - therapeutic use (3) 3
drug therapy (3) 3
endoscopic surgery (3) 3
endoscopy (3) 3
gastric mucosa - surgery (3) 3
gastroscopy - methods (3) 3
irinotecan (3) 3
medical prognosis (3) 3
medical research (3) 3
metallurgy (3) 3
metastases (3) 3
metastasis (3) 3
mice (3) 3
multicenter (3) 3
multivariate analysis (3) 3
mutation (3) 3
oncology, experimental (3) 3
pancreatic neoplasms - drug therapy (3) 3
phase-ii (3) 3
physics (3) 3
randomized controlled trial (3) 3
risk (3) 3
specific use of cosmetics or similar toiletpreparations (3) 3
stomach cancer (3) 3
studies (3) 3
surgical oncology (3) 3
tomography, x-ray computed (3) 3
- (2) 2
2nd-line chemotherapy (2) 2
2nd-line treatment (2) 2
adenocarcinoma (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) of the digestive system. Clinical data from 258 patients with... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 01/2018, Volume 109, Issue 1, pp. 215 - 224
Gemcitabine‐based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second‐line treatment(s) established yet.... 
biliary tract cancer | trametinib | refractory | gemcitabine | MEK inhibitor | CHOLANGIOCARCINOMA | MULTICENTER PHASE-II | 2ND-LINE CHEMOTHERAPY | BRAF | COMBINATION | HEPATOCELLULAR-CARCINOMA | INHIBITION | ONCOLOGY | S-1 | MUTATIONS | ASSOCIATION | Administration, Oral | Humans | Middle Aged | Pyrimidinones - adverse effects | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Transcription Factors - genetics | Whole Exome Sequencing | Protein Kinase Inhibitors - administration & dosage | Pyridones - administration & dosage | Gallbladder Neoplasms - drug therapy | Survival Analysis | Aged, 80 and over | Female | Aged | Pyrimidinones - administration & dosage | Biliary Tract Neoplasms - drug therapy | Nuclear Proteins - genetics | Neurofibromin 1 - genetics | Pyridones - adverse effects | Ampulla of Vater - pathology | Bile Duct Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Enzyme inhibitors | Antineoplastic agents | Biliary tract | Alternative splicing | Gemcitabine | Toxicity | Research funding | MAP kinase | Employees | Metastasis | Kinases | Ampulla of Vater | Cancer therapies | Survival | Patients | Bile duct | Studies | Allosteric properties | Chemotherapy | Medical prognosis | Response rates | Biomarkers | Gallbladder | Mutation | Safety | Pharmaceuticals | Index Medicus | Original
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4083 - 4083
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 1983 - 1983
Journal Article
Anticancer Research, ISSN 0250-7005, 03/2018, Volume 38, Issue 3, p. 1755
Background: No standard second-line chemotherapy has been yet established for gemcitabine-refractory biliary tract cancer (BTC). Patients and Methods: We... 
Tyrosine | Biliary tract | Carbohydrates | Gemcitabine | Liver | Clinical trials | Regression analysis | Multivariate analysis | Patients | Survival | Metastases | Chemotherapy | Medical prognosis | Protein-tyrosine kinase | Cancer
Journal Article
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, ISSN 1552-5260, 07/2018, Volume 14, Issue 7, pp. P1449 - P1450
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e15768 - e15768
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2015, Volume 75, Issue 3, pp. 457 - 464
Journal Article